53 results about "Naltrexone" patented technology

Described are pharmaceutical formulations comprising naltrexone and / or bupropion. Such pharmaceutical formulations can comprise extended-release, multilayer beads. Also described are methods of administering such formulations, such as for the treatment of overweight or obesity.

The invention discloses a preparation method of a natamaran hydrochloride intermediate, which comprises the following steps: repeatedly adding N-methylbenzylamine shown in a formula II and anhydrous formic acid into naltrexone shown in a formula I for reductive amination reaction to generate the natamaran hydrochloride intermediate shown in a formula III, the synthesis route is as follows: # imgabs0 obviously improves the reaction conversion rate of a raw material naltrexone and the effective conversion rate of converting the raw material naltrexone into a target product naarafarene hydrochloride intermediate shown as a formula III.

The disclosure relates to compositions comprising a phentermine and a unicyclic aminoketone and methods of use thereof. The methods of use include inducing weight loss or reducing weight gain in a human subject. The unicyclic aminoketone may be diethylpropion or bupropion. In some embodiments, the compositions further include tadalafil or naltrexone.

A single unit oral dose pharmaceutical composition for use as a medicament for separate, sequential or simultaneous administration with an agonist of a 5-hydroxytryptamine (5-HT) receptor;wherein the single unit oral dose pharmaceutical composition comprises a first active ingredient and a second active ingredient;wherein the first active ingredient is for absorption in the gastrointestinal tract from the oesophagus onwards and the second active ingredient is for absorption in the oral cavity; andwherein the first active ingredient is naltrexone in an amount of 0.01 to 10 mg and the second active ingredient is calcitriol in an amount of 80 to 200 ug.

An appetite suppressant composition may comprise at least one anorectic active ingredient; at least one of a nutritive substance, a cofactor; and optionally, an excipient. The anorectic active ingredient may comprise any one of phentermine, phendimetrazine, diethylpropion, naltrexone, and bupropion. The nutritive substance may comprise a protein source such as bovine collagen. The cofactor may comprise a chromium or selenium salt. In various embodiments, the compositions herein are provided in an oral capsule dosage form for GI-tract administration of the AAI. A method of suppressing appetite in individuals in need thereof are described.

A formulation of naltrexone that ameliorates undesirable localized reactions at the site of implantation.

Provided is an injectable sustained release pharmaceutical formulation, including 3-acyl-naltrexone or a pharmaceutically acceptable salt thereof, a biocompatible organic solvent, and optionally a biocompatible polymeric material. Also provided is a method for treating opioid use disorder or alcoholism, including administering the injectable sustained release pharmaceutical formulation to a subject in need thereof. The pharmaceutical formulation provides a sustained release profile after one single injection, and the plasma levels of naltrexone in minipigs could provide a sustained release for 2 months.

Disclosed herein are methods useful for the synthesis of benzylisoquinoline alkaloids ("BIA"), such as alkaloid morphinans. The disclosed methods can be used to produce thebaine, eastern papaverine, codeine, morphine, oxycodone, hydrocodone, oxymorphinone, hydromorphinone, naltrexone, naloxone, hydroxycodeinone, neolpinone, and / or buprenorphine.

Disclosed is a compound sustained release implant of naltrexone and risperidone, and a preparation method and application thereof, which belong to the technical field of implant preparation. The naltrexone compound sustained-release implant includes naltrexone, risperidone, a degradable material A, a degradable material B, an additive and a lubricant. By controlling a mass ratio of naltrexone to risperidone to be (20-30):1, a weight-average molecular weight of the degradable material A to be 10-15W, and a weight-average molecular weight of the degradable material B in risperidone microspheres to be 2W-4W, the compound sustained release implant of naltrexone and risperidone can not only effectively inhibit amphetamine type drug relapse and reduce side effects of risperidone, but also realize the synchronous release of naltrexone and risperidone.

An appetite suppressant composition may comprise at least one anorectic active ingredient; at least one of a nutritive substance, a cofactor; and optionally, an excipient. The anorectic active ingredient may comprise any one of phentermine, phendimetrazine, diethylpropion, naltrexone, and bupropion. The nutritive substance may comprise a protein source such as bovine collagen. The cofactor may comprise a chromium or selenium salt. In various embodiments, the compositions herein are provided in an oral capsule dosage form for GI-tract administration of the AAI. A method of suppressing appetite in individuals in need thereof are described.

A method of treating opioid use disorder (OUD) or alcohol use disorder (AUD) includes administering a pharmaceutically effective amount of a topical composition comprising an anhydrous suspension including naltrexone to an oral cavity of a subject for oral absorption therein. The topical composition is formulated to self-emulsify in an aqueous environment of the oral cavity.

Disclosed are methods and compositions for the treatment of dry eye. In particular, the invention relates to methods and compositions for treating dry eye based on topical application of opioid antagonists such as naltrexone.

Disclosed herein are methods that may be used for the synthesis of benzylisoquinoline alkaloids (“BIAs”) such as alkaloid morphinan. The methods disclosed can be used to produce thebaine, oripavine, codeine, morphine, oxycodone, hydrocodone, oxymorphone, hydromorphone, naltrexone, naloxone, hydroxycodeinone, neopinone, and / or buprenorphine. Compositions and organisms useful for the synthesis of BIAs, including thebaine synthesis polypeptides, purine permeases, and polynucleotides encoding the same, are provided.

The application belongs to the technical field of medicine synthesis, and provides a preparation method of naltrexone, wherein norethoxy-morphinone and cyclopropylmethanol are used as raw materials, and PdCl2 (Xantphos) is used as a catalyst to perform reaction. The application has the characteristics of simple operation, mild reaction condition and the like, and the yield and purity of the obtained product are high, and the application is more suitable for industrial production.

This application relates to a method for detecting related substances in a pharmaceutical composition containing naltrexone and risperidone, comprising the following steps: preparing a test solution from the pharmaceutical composition containing naltrexone and risperidone; and detecting the test solution using high-performance liquid chromatography (HPLC), wherein the HPLC detection conditions include: (1) a chromatographic column consisting of a C18 column and a silica-bonded phenyl column arranged in series; and (2) mobile phases A, B, and C being buffer solutions, acetonitrile, and methanol at different volume percentages, respectively; each buffer solution being an aqueous solution of sodium octanesulfonate with a pH of 2.25–2.35. The detection method can effectively separate and detect multiple related substances in a pharmaceutical composition containing naltrexone and risperidone.

Mu opioid receptor (MOR) antagonists that specifically and effectively reverse the acute and chronic toxicity of fentanyl and its analogs are provided. The antagonists were developed by modifying the structural skeleton of fentanyl and / or phenylfentanil. The antagonists compete with fentanyls at the MOR binding site and when bound, they reverse the toxicity of fentanyls more effectively and selectively or specifically than naloxone, naltrexone, and other epoxymorphinan-type opioids.

A recombinant microbial host cell having improved in vivo conversion of reticuline and derivatives thereof (such as thebaine and / or oripavine) to relevant downstream opioids (such as neopinone, oripavine, northebaine, nororipavine or morphinone) and related compounds (such as heroin, morphine, codeine, thebaine, oripavine, oxycodone, hydrocodone, hydromorphone, oxymorphone, buprenorphine, naltrexone, naloxone or nalbuphine), wherein the microbial (such as fungal) host cell is heterologously expressing at least one functional transporter protein capable of transporting reticuline or a derivative thereof (such as thebaine and / or oripavine) and a heterologously expressed enzyme capable of acting upon reticuline or a derivative thereof. The invention also relates to uses of the microbial host cells and methods of making an opioid compound and / or opioid precursor compound and / or opioid derivative of interest.

A combination therapy for use in treatment of substance abuse disorders, including alcohol use disorder (AUD) and opioid use disorder (OUD), includes both mitragynine (MG) and naltrexone (NTX). NTX is understood to be a mu opioid antagonist that is expected to block MG's analgesic effects. However, combining MG and NTX therefore results in a unique, unexpected, and beneficial treatment that decreases alcohol self-administration to a greater extent than either alone.

A method of treating a wound may include topically administering a statin composition including a statin selected from atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, or combination thereof. The statin composition may be administered in an ointment, powder, or liquid format. The method may also include topically administering one or more antimicrobial drugs and / or naltrexone.

The invention relates to a combined medicine of naltrexone or a structural analogue thereof and a URAT1 inhibitor and application of the combined medicine. The combined medicine can effectively reduce uric acid, treat hyperuricemia and treat renal injury or renal fibrosis. The combined medicine combines different action mechanisms of the two medicines, and can inhibit the activity of xanthine oxidase and reduce reabsorption of renal tubules at the same time, so that uric acid production is reduced, uric acid excretion is increased, and a stronger uric acid reducing effect is expected to be achieved; the damage caused by renal tubule dilatation can be improved, the fibrosis progress is relieved, and then the effect of relieving kidney injury is achieved.

The invention provides naloxone-loaded adhesive hydrogel as well as a preparation method and application thereof, and relates to the technical field of adhesive hydrogel. The naloxone-carrying adhesive hydrogel is obtained by cross-linking boric acid oxidized chondroitin sulfate and methacrylated gelatin; and naloxone and hectorite nano particles are loaded in the naloxone carrying adhesive hydrogel. The naloxone-loaded hydrogel constructed by the invention is used for repairing damage of bone and nervous tissues, naloxone is used as a small molecule drug, has more stable physical and chemical properties, is easier to store, and also has the functions of promoting osteogenesis and neurogenesis, so that the combined use of various bioactive factors is reduced; and the naloxone-carrying adhesive hydrogel has adhesive performance, can effectively fill a bone defect area and form a stable repair microenvironment, and accelerates the bone and nervous tissue regeneration efficiency.

Disclosed are antibodies that specifically bind to naloxone or naltrexone. Conjugates for producing the antibodies, and methods of producing the antibodies, are also disclosed. Also disclosed are methods of using the antibodies in direct assays of naloxone or naltrexone. Further disclosed are methods of using the antibodies to reduce naloxone or naltrexone interference in opiate assays.

To provide an agent that increases the expression of BAD, for use in the treatment of cancer in conjunction with a chemotherapeutic agent.SOLUTION: The inventors have discovered an agent that increases the expression of BAD, for use in the treatment of cancer in conjunction with a chemotherapeutic agent, wherein the agent is selected from the group consisting of 6-β-naltrexol, naloxone, methylnaltrexone, or pharmaceutically acceptable salts thereof.SELECTED DRAWING: Figure 1a

Disclosed herein are methods that may be used for the synthesis of benzylisoquinoline alkaloids (“BIAs”) such as alkaloid morphinan. The methods disclosed can be used to produce thebaine, oripavine, codeine, morphine, oxycodone, hydrocodone, oxymorphone, hydromorphone, naltrexone, naloxone, hydroxycodeinone, neopinone, and / or buprenorphine. Compositions and organisms useful for the synthesis of BIAs, including thebaine synthesis polypeptides, purine permeases, and polynucleotides encoding the same, are provided.

A subcutaneous biodegradable medical implant is disclosed utilizing naltrexone microspheres with magnesium stearate and polylactide-coglycolide, wherein the subcutaneous biodegradable medical implant is capable of releasing a dosage amount of the naltrexone from the implant following subcutaneous placement of the implant in vivo without causing undesirable reactions at the implantation site.

To provide a method for producing an antibody or a functional fragment thereof that can specifically bind to naloxone and naltrexone.SOLUTION: The method comprises the steps of: immunizing a non-human animal with a conjugate comprising the structure of Formula III, thereby inducing B cells that produce an antibody binding to the conjugate (A is -O-, -N-, or -S-; B is -CO-, a lower alkyl, -CONH-, -SO2-, or the like; C is a carrier protein; and R2 is an allyl or cyclopropyl group); and obtaining an antibody or a functional fragment thereof produced by the B cells.SELECTED DRAWING: Figure 1

Bivalent ligands which bind to MOR-CCR5 heterodimers are provided. The bivalent ligands comprise two discrete pharmacophores, naltrexone and maraviroc, linked by a spacer and bind to MOR-CCR5 heterodimers, e.g. at the surface of a cell. The bivalent ligands are useful in assays to detect MOR-CCR5 heterodimers, as therapeutic agents to prevent and / or treat diseases characterized by the presence of MOR-CCR5 heterodimers.

Disclosed are method for predicting naltrexone response in subjects with AUD. In some embodiments, the methods include performing or having performed one or more methylation assays on a genomic DNA sample isolated from the subject to determine the methylation status of one or more regions of the isolated genomic DNA, wherein the one or more regions are subsequences of a gene selected from a mu opioid receptor (OPRM1) gene, a catechol-O-methyltransferase (COMT) gene, and a dopamine transporter (SLC6A3) gene, wherein the methylation status of the one or more regions of the isolated genomic DNA determined is predictive of naltrexone response in the subject. Also provided are method for treating patients diagnosed with AUD with the medication naltrexone based on a methylation status of a combination of specific methylation sites located associated with an OPRM1 gene, a COMT gene, and / or an SLC6A3 gene in obtained from each AUD patient.

The present invention provides methods for treating, preventing, or delaying the onset of Charcot-Marie-Tooth Disease type 1A (CMT1A), by administering to a subject in need thereof a combination comprising baclofen, sorbitol and naltrexone, or a pharmaceutically acceptable salt thereof.

To provide antibodies or functional fragments thereof which can specifically bind to naloxone and / or naltrexone, and methods of production thereof.SOLUTION: The invention provides: antibodies or functional fragments thereof which include heavy chain variable regions CDR1, CDR2, and CDR3 each having a specific amino acid sequence and light chain variable regions CDR1, CDR2, and CDR3 each having a specific amino acid sequence; methods of production of the antibodies or functional fragments thereof; and compositions comprising the antibodies or functional fragments thereof and detectable labels attached thereto.SELECTED DRAWING: Figure 1